Risk evaluation for admission CAD in patients with specific immune-mediated inflammatory diseases
| Patient no | Admission CAD events | Follow-up years (mean) | Admission CAD incidence rate per 100 PY | Crude HR (95% CI) | P value | Adjusted HR* (95% CI) | P value | |
| Main analysis | ||||||||
| All IMID | 58 862 | 2139 | 5.3 | 0.69 | 1.93 (1.84 to 2.02) | <0.0001 | 1.30 (1.24 to 1.37) | <0.0001 |
| Rheumatoid arthritis | 26 820 | 1141 | 5.6 | 0.76 | 2.12 (2.00 to 2.25) | <0.0001 | 1.21 (1.13 to 1.28) | <0.0001 |
| Sjogren’s syndrome | 17 530 | 534 | 4.6 | 0.66 | 1.86 (1.71 to 2.03) | <0.0001 | 1.25 (1.15 to 1.37) | <0.0001 |
| SLE | 10 014 | 281 | 5.5 | 0.51 | 1.42 (1.27 to 1.60) | <0.0001 | 1.78 (1.58 to 2.01) | <0.0001 |
| IIM | 1488 | 59 | 4.7 | 0.84 | 2.37 (1.83 to 3.05) | <0.0001 | 1.63 (1.26 to 2.10) | 0.0002 |
| Systemic sclerosis | 1373 | 84 | 5.0 | 1.22 | 3.44 (2.78 to 4.26) | <0.0001 | 1.96 (1.58 to 2.43) | <0.0001 |
| Behcet’s disease | 1161 | 18 | 6.7 | 0.23 | 0.65 (0.41 to 1.03) | 0.065 | 0.90 (0.56 to 1.42) | 0.64 |
| Systemic vasculitis | 476 | 22 | 5.2 | 0.89 | 2.53 (1.67 to 3.83) | <0.0001 | 1.20 (0.79 to 1.83) | 0.38 |
| General population | 1 000 000 | 20 247 | 5.7 | 0.36 | Reference | Reference | ||
| Subgroup analysis | ||||||||
| Men aged <45 years, women <50 years | ||||||||
| All IMID | 25 674 | 346 | 5.9 | 0.23 | 2.6 (2.32 to 2.9) | <0.0001 | 1.71 (1.51 to 1.94) | <0.0001 |
| Rheumatoid arthritis | 9534 | 102 | 6.2 | 0.17 | 1.91 (1.57 to 2.33) | <0.0001 | 1.16 (0.94 to 1.42) | 0.158 |
| Sjogren’s syndrome | 6306 | 58 | 5.1 | 0.18 | 2.14 (1.65 to 2.77) | <0.0001 | 1.43 (1.09 to 1.86) | 0.009 |
| SLE | 7559 | 143 | 5.9 | 0.32 | 3.58 (3.03 to 4.23) | <0.0001 | 2.85 (2.36 to 3.43) | <0.0001 |
| IIM | 660 | 13 | 5.6 | 0.35 | 3.99 (2.31 to 6.88) | <0.0001 | 1.73 (0.99 to 3.03) | 0.054 |
| Systemic sclerosis | 493 | 18 | 6.1 | 0.60 | 6.78 (4.27 to 10.78) | <0.0001 | 3.18 (1.99 to 5.09) | 0.0001 |
| Behcet’s disease | 877 | 6 | 6.9 | 0.10 | 1.1 (0.49 to 2.44) | 0.820 | 0.74 (0.33 to 1.66) | 0.472 |
| Systemic vasculitis | 245 | 6 | 6.0 | 0.41 | 4.56 (2.05 to 10.15) | <0.0001 | 2.27 (1.01 to 5.07) | 0.046 |
| General population | 615 280 | 3294 | 6.0 | 0.09 | Reference | Reference | ||
| Men aged ≥45 years, women ≥50 years | ||||||||
| All IMID | 33 188 | 1793 | 4.8 | 1.11 | 1.3 (1.23 to 1.36) | <0.0001 | 1.18 (1.12 to 1.24) | <0.0001 |
| Rheumatoid arthritis | 17 286 | 1039 | 5.3 | 1.14 | 1.32 (1.24 to 1.4) | <0.0001 | 1.15 (1.08 to 1.23) | <0.0001 |
| Sjogren’s syndrome | 11 224 | 476 | 4.4 | 0.97 | 1.14 (1.04 to 1.25) | 0.05 | 1.16 (1.06 to 1.28) | 0.002 |
| SLE | 2455 | 138 | 4.3 | 1.31 | 1.53 (1.29 to 1.8) | <0.0001 | 1.26 (1.06 to 1.49) | 0.009 |
| IIM | 828 | 46 | 4.1 | 1.37 | 1.6 (1.2 to 2.13) | 0.002 | 1.41 (1.06 to 1.89) | 0.020 |
| Systemic sclerosis | 880 | 66 | 4.4 | 1.69 | 1.98 (1.55 to 2.52) | <0.0001 | 1.62 (1.27 to 2.06) | <0.0001 |
| Behcet’s disease | 284 | 12 | 6.1 | 0.69 | 0.79 (0.45 to 1.4) | 0.422 | 0.92 (0.52 to 1.61) | 0.761 |
| Systemic vasculitis | 231 | 16 | 4.3 | 1.62 | 1.9 (1.16 to 3.1) | 0.011 | 0.98 (0.6 to 1.6) | 0.942 |
| General population | 384 720 | 16 953 | 5.1 | 0.86 | Reference | Reference |
*Adjusted by age, sex, DM, HTN, dyslipidaemia, renal failure, atherosclerosis, steroids, antidiabetics, diuretics, beta-blockers, calcium channel blocker, lipid lowing agents, aspirin, non-steroid anti-inflammatory drugs.
CAD, coronary artery disease; DM, diabetes mellitus; HTN, hypertension; IIM, idiopathic inflammatory myositis; IMID, immune-mediated inflammatory disease; PY, person-years; SLE, systemic lupus erythematosus.